



# ARK™ Lamotrigine Assay


This ARK Diagnostics, Inc. package insert for the ARK Lamotrigine Assay must be read carefully prior to use. Package insert instructions must be followed accordingly. Reliability of the assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

Report any serious incident that has occurred in relation to the device to the manufacturer and the appropriate competent authority as applicable. A Summary of Safety and Performance is available through Eudamed (European database on medical devices), SRN: US-MF-000023925.


## Customer Service



48089 Fremont Blvd  
 Fremont, CA 94538 USA  
 Tel: 1-877-869-2320  
 Fax: 1-510-270-6298  
 customersupport@ark-tdm.com  
 www.ark-tdm.com



Emergo Europe  
 Westervoortsedijk 60  
 6827 AT Arnhem  
 The Netherlands



MedEnvoy Switzerland  
 Gotthardstrasse 28  
 6302 Zug  
 Switzerland

## Key to Symbols Used

	Batch code	 YYYY-MM-DD	Use by/Expiration date
	Catalog Number		Manufacturer
	Authorized Representative		CE Mark with notified body number
	In Vitro Diagnostic Medical Device		Temperature limitation
	Consult Instructions for Use		Reagent 1/ Reagent 2
<b>Rx Only</b>	For Prescription Use Only		

## 1 Name

### **ARK<sup>TM</sup> Lamotrigine Assay**

## 2 Intended Use

The ARK Lamotrigine Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of lamotrigine in human serum or plasma on automated clinical chemistry analyzers. Lamotrigine concentrations can be used as an aid in management of patients treated with lamotrigine.

## 3 Summary and Explanation of the Test

Lamotrigine (LAMICTAL<sup>®</sup>, 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine) is an anti-convulsant drug approved for use in the treatment of epilepsy and is often prescribed as monotherapy or as one component of a multiple anti-epileptic drug therapy. <sup>1</sup>

## 4 Principles of the Procedure

ARK Lamotrigine Assay is a homogeneous immunoassay based on competition between drug in the specimen and lamotrigine labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to the antibody reagent. As the latter binds antibody, enzyme activity decreases. In the presence of drug from the specimen, enzyme activity increases and is directly proportional to the drug concentration. Active enzyme converts the coenzyme nicotinamide adenine dinucleotide (NAD) to NADH that is measured spectrophotometrically as a rate of change in absorbance. Endogenous serum G6PDH does not interfere with the results because the coenzyme NAD functions only with the bacterial enzyme used in the assay.

## 5 Reagents

REF	Product Description	Quantity/Volume
5023-0001-00	<b>ARK Lamotrigine Assay</b> <b>Reagent [R1] – Antibody/Substrate</b> rabbit polyclonal antibodies to lamotrigine, glucose-6-phosphate, nicotinamide adenine dinucleotide, bovine serum albumin, preservatives, and stabilizers	1 X 28 mL
	<b>Reagent [R2] – Enzyme</b> Lamotrigine labeled with bacterial G6PDH, buffer, bovine serum albumin, preservatives, and stabilizers	1 X 14 mL

## Reagent Handling and Storage

ARK Lamotrigine Assay reagents are provided liquid, ready to use and may be used directly from the refrigerator. When not in use, reagents must be stored at 2–8°C (36–46°F), upright and with screw caps tightly closed. If stored as directed, reagents are stable until the expiration date printed on the label. Do not freeze reagents. Avoid prolonged exposure to temperatures above 32°C (90°F). **Improper storage of reagents can affect assay performance.**

## 6 Warnings and Precautions

- For **In Vitro Diagnostic** Use. For prescription use only.
- Reagents **R1** and **R2** are provided as a matched set and should not be interchanged with reagents from different lot numbers.

## 7 Specimen Collection and Preparation for Analysis

- Each laboratory is responsible for supplying a valid specimen for analysis according to their quality procedures.
- Serum or plasma is required. For consistency, using the same specimen matrix for individual patients is a good practice. A steady state, trough (pre-dose) sample is generally accepted as most consistent for therapeutic drug monitoring of lamotrigine. Time of blood draw since last dose should be noted.
- Whole blood cannot be used. The following anticoagulants may be used with this assay.
  - Sodium heparin
  - Lithium heparin
  - Potassium EDTA
- **DO NOT USE GEL SEPARATORS.** Blood collection must be performed with collection tubes compatible for use with therapeutic drug monitoring (TDM).
- Follow the collection tube manufacturer's recommendations for collection, processing and centrifugation
- CLSI document GP44-A4 outlines procedures for minimizing artifacts due to specimen collection and handling for common laboratory tests.<sup>29</sup>
- Do not induce foaming and avoid repeated freezing and thawing to preserve the integrity of the specimen from the time it is collected until the time it is assayed.
- Fibrin, red blood cells, and other particulate matter may cause an erroneous result. Ensure adequate centrifugation.

- The presence of bubbles or foam on specimens may lead to short samples and erroneous results.
- Clarified specimens may be stored up to one week at 2 to 8°C. If testing will be delayed more than one week, specimens may be stored frozen ( $\leq -10^{\circ}\text{C}$ ) up to four weeks prior to being tested (acceptance criterion  $\pm 10\%$ ). Care should be taken to limit the number of freeze-thaw cycles. Specimens were shown to withstand 3 freeze-thaw cycles when stored at  $-20^{\circ}\text{C}$ .
- **Handle all patient specimens as if they were potentially infectious.**

## 8 Procedure

### Materials Provided

ARK Lamotrigine Assay – **REF** 5023-0001-00

### Materials Required – Provided Separately

ARK Lamotrigine Calibrator – **REF** 5023-0002-00

Quality Controls – ARK Lamotrigine Control – **REF** 5023-0003-00

### Instruments

Reagents **R1** and **R2** may need to be transferred to analyzer-specific reagent containers prior to use. Avoid cross-contamination of **R1** and **R2**.

Many automated clinical chemistry analyzers with photometric rate determination at 340 nm are suitable. Consult the analyzer-specific application sheet for programming the ARK Lamotrigine Assay, available from your distributor or ARK Customer Service. Application Protocol Sheets which have been CLIA categorized or bear the CE Mark have been verified by the manufacturer. It is the responsibility of the laboratory to perform all appropriate validation for use of the assay with other settings or analyzers.

Refer to the instrument-specific operator's manual for daily maintenance

### Assay Sequence

To run or calibrate the assay, see the instrument-specific operator's manual.

### Calibration

Perform a full calibration (6- point) procedure using the ARK Lamotrigine Calibrators A, B, C, D, E, and F; run calibrators in duplicate. Calibration is required with each new reagent kit lot number. Verify the calibration curve with at least two levels of quality controls according to the established laboratory quality assurance plan.

### **When to Re-Calibrate**

- Whenever a new lot number of reagents is used
- Whenever indicated by quality control results
- Whenever required by standard laboratory protocols

### **Quality Control (QC)**

Laboratories should establish QC procedures for the ARK Lamotrigine Assay. All quality control requirements and testing should be performed in conformance with local, state and/or federal regulations or accreditation requirements.

Good laboratory practice suggests that at least two levels (low and high medical decision points) of quality control be tested each day patient samples are assayed and each time a calibration is performed. Monitor the control values for any trends or shifts. If any trends or shifts are detected, or if the control does not recover within the specified range, review all operating parameters according to your clinical laboratory quality procedures. Contact Customer Service for further assistance.

### **Manual Dilution Protocol**

To estimate drug levels in specimens exceeding the upper limit of quantitation, manually dilute the specimen with zero calibrator (CAL A). Multiply the assayed result by the dilution factor. A four-fold dilution factor is suggested.

$$\text{Manual Dilution Factor} = \frac{(\text{Volume of Specimen} + \text{Volume of CAL A})}{\text{Specimen Volume}}$$

## **9 Results**

Report result units as µg/mL or µmol/L. To convert results from µg/mL lamotrigine to µmol/L lamotrigine, multiply µg/mL by 3.90. The lamotrigine value from this assay should be used in conjunction with other clinical information. Refer to the instrument specific operator's manual for any result error codes.

## **10 Limitations of Procedure**

This assay is designed for use with serum or plasma only; refer to the sections **Specimen Collection and Preparation for Analysis**. It is generally good practice to use the same method (as well as matrix) consistently for individual patient care due to the potential for method-to-method variabilities. See the section **Expected Values** below.

## 11 Expected Values

The reference range of drug concentrations which is quoted should only imply a lower limit below which a therapeutic response is relatively unlikely to occur, and an upper limit above which toxicity is relatively likely to occur in the specific patient populations studied. Generally, clinicians using reference ranges such as these should be aware that, because of individual variation, patients may achieve therapeutic benefit with serum drug concentrations outside of these ranges and may experience toxicity with levels below the lower limit of the reference range. Sampling time should be standardized such that trough serum concentrations are measured just before the next dosage, preferably in the morning.

A therapeutic range for lamotrigine has not been well established. Some reports in the literature suggest a target range for steady-state concentrations of 3 to 15 µg/mL.<sup>2-5</sup> However, there is not a clear relationship between lamotrigine serum concentrations and clinical response.<sup>2-5</sup> Due to individual patient differences and other co-administered medications, considerable overlap in lamotrigine concentrations has been observed between serum responders and non-responders as well as between serum levels associated with seizure control and adverse effects.<sup>1-14</sup> In one study, the highest mean serum level (trough) reported was 8.8 µg/mL, and less than 15% of patients reported an adverse event at serum concentrations less than 10 µg/mL.<sup>15</sup> Mild to moderate adverse effects are more commonly associated with patients with lamotrigine concentrations above 15 µg/mL.<sup>2,5,14</sup>

Co-medications affect clearance of lamotrigine with enzyme-inducers increasing and valproic acid decreasing clearance.<sup>16</sup> Lamotrigine clearance is higher in children than in adults<sup>17,18</sup> and moderately reduced in the elderly.<sup>18</sup> Clearance may be increased during pregnancy,<sup>19-22</sup> but such increase is attenuated in women co-medicated with valproic acid.<sup>20</sup> Acute overdoses associated with serum levels above 40 µg/mL (156 µmol/L) have been reported.<sup>23,24</sup>

Lamotrigine drug concentrations should not be the only means of therapeutic drug management. The assay should be used in conjunction with information available from clinical evaluations and other diagnostic procedures. Clinicians should carefully monitor patients during therapy initiation and dosage adjustments. Multiple measurements of lamotrigine may be needed.

## 12 Specific Performance Characteristics

The following performance characteristics were obtained on the Roche/Hitachi 917 System. Each laboratory is responsible for verification

of performance using instrument parameters established for their analyzer.

## **Sensitivity**

### Limit of Quantitation (LOQ)

The LOQ of the ARK Lamotrigine Assay was determined according to CLSI EP17-A and is defined as the lowest concentration for which acceptable inter-assay precision and recovery is observed ( $\leq 20\%$  CV with  $\pm 15\%$  recovery). The LOQ was determined to be 0.85  $\mu\text{g/mL}$ , and may depend on analyzer-specific performance.

## **Assay Range**

The range of the assay is 0.85 to 40.00  $\mu\text{g/mL}$ . Report results below this range as  $<0.85$   $\mu\text{g/mL}$  or below the analyzer-specific lower LOQ established in your laboratory. Report results above this range as  $>40.00$   $\mu\text{g/mL}$  or above the analyzer-specific upper LOQ established in your laboratory.

## **Recovery**

Accuracy (analytical recovery) was performed by adding concentrated lamotrigine drug into human serum negative for lamotrigine. A stock concentrate of highly pure lamotrigine was added volumetrically to human serum negative for lamotrigine, representing drug concentrations across the assay range. Six replicates of each sample were assayed on an automated clinical chemistry analyzer. The results were averaged and compared to the target concentration and percent recovery calculated. Results are shown below.

$$\% \text{ Recovery} = 100 \times \frac{\text{Mean recovered concentration}}{\text{Theoretical concentration}}$$

<b>Theoretical Concentration (<math>\mu\text{g/mL}</math>)</b>	<b>Mean Recovered Concentration (<math>\mu\text{g/mL}</math>)</b>	<b>Percent Recovery</b>
0.85	0.84	98.2
1.00	0.99	99.2
2.50	2.48	99.3
5.00	5.25	105.1
11.00	10.97	99.7

15.00	14.80	98.7
30.00	29.16	97.2
40.00	38.33	95.8

Mean percent recovery: 99.2

## Linearity

Linearity studies were performed as suggested in CLSI/NCCLS Protocol EP6-A. A 48.00 µg/mL serum sample was prepared and dilutions were made proportionally with human serum negative for lamotrigine. Lamotrigine concentrations ranged from 1.00 to 48.00 µg/mL. Linearity at specific dilutions was considered acceptable if the percent difference was ±10% between the predicted 1<sup>st</sup> and 2<sup>nd</sup> order regressed values. Results are shown below.

Estimated Value (µg/mL)	Results (µg/mL)	1st Order Predicted Results	2nd Order Predicted Results	% Difference
1.00	0.96	1.13	1.21	7.1
2.00	2.08	2.11	2.17	3.1
4.00	4.16	4.06	4.10	0.9
8.00	8.18	7.97	7.96	-0.1
12.00	12.01	11.88	11.83	-0.4
16.00	16.18	15.78	15.72	-0.4
24.00	22.78	23.60	23.53	-0.3
32.00	30.84	31.41	31.39	-0.1
40.00	40.13	39.23	39.30	0.2
48.00*	46.88	47.04	47.27	0.5

\*Concentration exceeds the reportable limit.


## Method Comparison

Correlation studies were performed using CLSI/NCCLS Protocol EP9-A2. Results from the ARK Lamotrigine Assay were compared with results from high performance liquid chromatography (HPLC, Study 1) and a turbidimetric immunoassay (Study 2).

### Study 1

Lamotrigine concentrations by HPLC ranged 1.00 to 36.70 µg/mL. ARK lamotrigine values ranged 0.97 to 36.32 µg/mL. Results of the Passing-Bablok<sup>25</sup> regression analysis for the study are shown below (with 95% confidence limits).


Slope	1.01	(0.99 to 1.03)
y-intercept	0.37	(0.22 to 0.55)
Correlation Coefficient (r <sup>2</sup> )	0.97	(0.96 to 0.98)
Number of Samples	193	



## Study 2

Lamotrigine concentrations by the turbidimetric immunoassay ranged from 2.28 µg/mL to 37.70 µg/mL. ARK lamotrigine values ranged 2.51 to 36.32 µg/mL. Results of the Passing-Bablok<sup>25</sup> regression analysis for the study are shown below (with 95% confidence limits).

Slope	0.93	(0.89 to 0.97)
y-intercept	0.41	(0.07 to 0.74)
Correlation Coefficient ( $r^2$ )	0.96	(0.94 to 0.97)
Number of Samples	77	



## Precision

Precision was determined as described in CLSI/NCCLS Protocol EP5-A2. Tri-level controls and three human serum pooled specimens containing lamotrigine were used in the study. Each level was assayed in quadruplicate twice a day for 20 days. Each of the runs per day was separated by at least two hours. The within run, between day, total SD, and percent CVs were calculated. Results are shown below. Acceptance criteria:  $\leq 10\%$  total CV.

Sample	N	Mean ( $\mu\text{g/mL}$ )	Within Run		Between Day		Total		
			SD	CV (%)	SD	CV (%)	SD	CV (%)	
ARK Lamotrigine Control									
LOW	160	2.08	0.07	3.4	0.05	2.5	0.08	4.1	
MID	160	11.70	0.42	3.6	0.28	2.4	0.49	4.2	
HIGH	160	24.23	0.99	4.1	1.06	4.4	1.47	6.1	
Calibrator/Control Matrix	40	38.04	2.05	5.4	0.95	2.5	2.27	6.0	
Human Serum									
LOW	160	2.41	0.08	3.5	0.09	3.7	0.12	5.2	
MID	160	10.75	0.41	3.8	0.42	3.9	0.59	5.5	
HIGH	160	25.84	1.33	5.2	1.12	4.3	1.88	7.3	
Pooled Human Serum	40	38.24	2.78	7.3	0.61	1.6	3.38	8.8	

## Interfering Substances

Interference studies were conducted using CLSI/NCCLS Protocol EP7-A2 as a guideline. Clinically high concentrations of the following potentially interfering substances in serum with known levels of lamotrigine (approximately 3 and 15  $\mu\text{g/mL}$ ) were evaluated. Each sample was assayed using the ARK Lamotrigine Assay, along with a serum control of lamotrigine. Measurement of lamotrigine resulted in  $\leq 10\%$  error in the presence of interfering substances at the levels tested.

Interfering Substance	Interferent Concentration	Percentage Recovery	
		3 µg/mL Lamotrigine	15 µg/mL Lamotrigine
Albumin	12 g/dL	101.5	103.4
Bilirubin - conjugated	70 mg/dL	93.6	102.6
Bilirubin - unconjugated	70 mg/dL	97.1	105.0
Cholesterol	623 mg/dL	98.9	103.8
Gamma-Globulin	12 g/dL	106.8	104.4
Hemoglobin	1000 mg/dL	98.2	97.0
Intralipid®	1000 mg/dL	94.5	94.3
Rheumatoid Factor	1100 IU/mL	107.3	108.9
Triglycerides	618 mg/dL	101.7	104.0
Uric Acid	30 mg/dL	101.0	99.6

### Specificity

Lamotrigine's major metabolite, medications that may be routinely co-administered with lamotrigine and other anti-epileptic drugs were tested to determine whether these compounds affect the quantitation of lamotrigine concentrations using the ARK Lamotrigine Assay. High levels of these compounds were spiked into serum pools containing low (3 µg/mL) and high (15 µg/mL) therapeutic levels of lamotrigine. The samples were analyzed and the lamotrigine concentrations of samples containing interferent were compared to the serum control.

### Metabolites

Lamotrigine is metabolized predominantly by UDP-glucuronyltransferase to form a pharmacologically inactive metabolite, 2-N-glucuronide.<sup>26-28</sup> Lamotrigine-2-N-methyl has been detected in human plasma by HPLC and capillary electrophoresis.<sup>27,28</sup> Other minor metabolites, lamotrigine-2-N-oxide, and lamotrigine-5-N-glucuronide have been proposed.<sup>26</sup> Lamotrigine-2-N-glucuronide, Lamotrigine-2-N-methyl and Lamotrigine-2-N-oxide metabolites were tested for cross-reactivity. These metabolites were spiked into two separate samples each containing low and high lamotrigine concentrations of 3 and 15 µg/mL, respectively.

Metabolite*	Metabolite Concentration (µg/mL)	Percentage Cross-Reactivity	
		Lamotrigine (3 µg/mL)	Lamotrigine (15 µg/mL)
Lamotrigine-2-N-glucuronide	50.0	2.41	1.86
	25.0	2.57	1.09
	12.5	2.91	1.92
	9.0	2.15	1.57
Lamotrigine-2-N-methyl	400.0	0.04	0.21
	200.0	0.07	0.02
	80.0	0.10	0.24
Lamotrigine-2-N-oxide	80.0	3.69	3.63
	40.0	3.94	3.64
	20.0	3.72	3.14
	10.0	3.88	1.30

\* The literature suggests there is weak evidence for the presence of minor metabolites in human plasma.<sup>25</sup>

### Drug that Cross-React

Cross-reactivity of the antibody to trimethoprim at the following concentration was tested. A high concentration was spiked into normal human serum with known levels of lamotrigine (approximately 3 and 15 µg/mL) and assayed along with a serum control of lamotrigine. The results are shown below.

Trimethoprim (µg/mL)	Percent Cross-Reactivity		Percent Recovery	
	Lamotrigine (3 µg/mL)	Lamotrigine (15 µg/mL)	Lamotrigine (3 µg/mL)	Lamotrigine (15 µg/mL)
40.0	4.4	3.0	156.0	108.0

Care should be taken when interpreting ARK Lamotrigine results if trimethoprim is also being administered to the patient.

### Drug Interference

Lamotrigine-selective antibody did not crossreact with most other anti-epileptic or coadministered drugs tested. Due to structural similarities with lamotrigine, high trimethoprim levels may interfere. A high concentration of each compound was spiked into normal human serum with known levels of lamotrigine (approximately 3 and 15 µg/mL) and assayed along with a

serum control of lamotrigine. Measurement of lamotrigine resulted in  $\leq 10\%$  error in the presence of drug compounds at the levels tested.

Compound	Conc. Tested ( $\mu\text{g/mL}$ )	Percentage Recovery	
		3 $\mu\text{g/mL}$ Lamotrigine	15 $\mu\text{g/mL}$ Lamotrigine
Acetaminophen	200	103.7	99.1
Acetazolamide	100	101.2	99.2
Acetylsalicylic acid	1000	100.8	100.7
Amikacin	100	95.7	97.0
Amitriptyline	20	99.0	97.9
Amoxapine	40	104.7	101.2
Amphotericin B	100	94.0	91.6
Ampicillin	100	97.7	94.1
Ascorbic Acid	100	98.5	94.4
Baclofen	100	95.8	90.9
Bupropion	40	98.8	106.2
Caffeine	100	101.3	103.2
Carbamazepine	120	104.3	103.2
Carbamazepine-10, 11 epoxide	120	101.7	99.0
10-Hydroxy carbamazepine	100	96.2	94.3
Chloramphenicol	250	103.7	98.4
Chlorpromazine	20	97.2	95.0
Citalopram	20	98.0	97.5
Clobazam	100	103.4	105.6
Clonazepam	20	97.6	96.4
Cyclosporin A	40	101.7	99.4
Diazepam	20	101.1	97.7
Digoxin	80	103.4	97.6
Doxepin	20	101.6	103.1
Erythromycin	200	103.6	103.9
Ethanol	4000	94.0	98.2
Ethotoin	100	101.3	101.9
Ethosuximide	250	101.0	96.4

Compound	Conc. Tested (µg/mL)	Percentage Recovery	
		3 µg/mL Lamotrigine	15 µg/mL Lamotrigine
Felbamate	250	103.0	101.4
Fluoxetine	20	102.2	97.0
Furosemide	100	99.8	97.1
Gabapentin	200	103.8	98.1
Gentamicin	100	99.8	98.6
Haloperidol	20	104.1	100.3
Heparin	200 U/mL	99.0	100.5
Ibuprofen	500	101.6	96.2
Imipramine	20	99.6	97.7
Kanamycin B	200	98.5	100.5
Levetiracetam	400	103.6	101.9
Lidocaine	100	101.6	101.8
Lincomycin	1000	106.0	99.7
Mephentoin	100	95.7	103.9
Mesoridazine	40	97.6	101.7
Methicillin	250	95.2	99.4
Naproxen	600	97.3	104.8
Neomycin	1000	100.8	101.6
Niacin	100	97.8	105.8
Nitrazepam	20	101.5	103.9
Nortriptyline	20	96.6	104.9
Olanzapine	20	99.5	102.2
Oxcarbazepine	200	97.3	100.5
Paroxetine	40	101.6	100.0
2-phenyl-ethyl- malonamide (PEMA)	1000	100.1	100.9
Penicillin V	100	100.4	101.4
Perphenazine	100	99.5	103.2
Phenobarbital	200	101.0	98.9
Phenytoin	200	100.0	100.8
Pregabalin	200	99.6	98.4

Compound	Conc. Tested (µg/mL)	Percentage Recovery	
		3 µg/mL Lamotrigine	15 µg/mL Lamotrigine
Primidone	100	98.7	102.5
Procainamide	100	100.6	101.9
Prochlorperazine	40	99.4	90.3
Ranitidine	100	104.0	97.8
Rifampin	100	101.6	97.7
Risperidone	20	98.0	100.2
Sertraline	100	101.5	101.9
Spectinomycin	100	97.7	103.1
Stiripentol	100	102.3	101.6
Sulfamethoxazole	400	99.2	99.2
Theophylline	200	98.7	97.9
Thioridazine	20	102.9	101.3
Tiagabine	200	100.9	97.8
Tobramycin	100	98.8	96.9
Topiramate	250	100.3	96.7
Valproic Acid	600	100.8	96.8
Vancomycin	250	96.5	95.0
Vigabatrin	150	97.8	101.0
Zonisamide	400	97.9	99.6

### 13 References

1. Prescribing Information for LAMICTAL® GlaxoSmithKline, September 2009, [www.lamictal.com](http://www.lamictal.com).
2. Patsalos, P. N. et al. 2008. Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia* **49**:1239 – 1276.
3. Morris, R. G. et al. 1998. Lamotrigine and therapeutic drug monitoring: Retrospective survey following the introduction of a routine service. *Br J Clin Pharmacol* **46**:547 – 551.
4. Johannessen, S. I. et al. 2003. Therapeutic drug monitoring of the newer antiepileptic drugs. *Ther Drug Monit* **25**:347 – 363.

5. Johannessen, S. I. and Tomson, T. 2006. Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed? *Clin Pharmacokinet* **45**:1061 – 1075.
6. Matsuo, F. 1999. Lamotrigine. *Epilepsia* **40**(Suppl 5):S30 – 36.
7. Hachad, H. et al. 2002. New antiepileptic drugs: Review on drug interactions. *Ther Drug Monit* **24**:91 – 103.
8. Patsalos, P. N. et al. 2002. The importance of drug interactions in epilepsy therapy. *Epilepsia* **43**:365 – 385.
9. Besag, F. M. et al. 1998. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? *Epilepsia* **39**:183 – 187.
10. Eriksson, A. S. et al. 1996. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. *Epilepsia* **37**:769 – 773.
11. May, T. W. et al. 1996. Serum concentrations of lamotrigine in epileptic patients: The influence of dose and comedication. *Ther Drug Monit* **18**:523 – 531.
12. Yau, M. K. et al. 1992. Effect of valproate on the pharmacokinetics of lamotrigine (Lamictal) at steady state. *Epilepsia* **33** (Suppl 3):82.
13. Besag, F. M. et al. 2000. Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. *Epilepsia* **41**:624 – 627.
14. Besag, F. M. et al. 1998. The role of blood level monitoring in assessing lamotrigine toxicity. *Epilepsia* **36**(S6):131.
15. Hirsch, L. J. et al. 2004. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. *Neurology* **63**:1022 – 1026.
16. Rivas, N. et al. 2008. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. *Ther Drug Monit* **30**:483 – 489.
17. Bartoli, A. et al. 1997. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: A prospective study with preliminary assessment of correlations with clinical response. *Ther Drug Monit* **19**:252 – 260.
18. Perucca, E. 2006. Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. *Clin Pharmacokinet* **45**:351 – 363.
19. Petrenaite, V. et al. 2005. Individual changes in lamotrigine plasma concentrations during pregnancy. *Epilepsy Res* **65**:185 – 188.
20. Tomson, T. et al. 2006. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. *Neurology* **67**:1297 – 1299.

21. Pennel, P. B. et al. 2008. Lamotrigine in pregnancy. Clearance, therapeutic drug monitoring, and seizure frequency. *Neurology* **70**: 2130 – 2136.
22. Ohman, I. et al. 2008. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. *Epilepsia* **49**:1075 – 1080.
23. Braga, A. J. and Chidley, K. 2007. Self-poisoning with lamotrigine and pregabalin. *Anaesthesia* **62**: 524 – 527.
24. Reimers, A. and Reinholt, G. 2007. Acute lamotrigine overdose in an adolescent. *Ther Drug Monit* **29**:669 – 670.
25. Bablok, W. et al. 1988. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry. Part III. *J. Clin Chem Clin Biochem* **26**:783 – 790.
26. Beck, O. et al. 2006. Determination of Lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. *Ther Drug Monit* **28**:603 – 607.
27. Saracino, M. A. et al. 2007. Rapid HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma. *J. Sep. Sci.* **30**:2249 – 2255.
28. Pucci, V. et al. 2005. Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography. *Electrophoresis* **26**:935 – 942
29. . CLSI. *Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guideline—Fourth Edition*. CLSI document GP44-A4. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.

## 14 Trademarks

**ARK**<sup>™</sup> is a trademark of **ARK** Diagnostics, Inc.

Other brand or product names are trademarks of their respective holders.



**ARK Diagnostics, Inc.**  
**Fremont, CA 94538 USA**

Revised May 2026  
 1600-0179-00 Rev 08